Edgewise Therapeutics, Inc. — 2021 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2021; it does not provide standalone fourth-quarter results. Edgewise is a clinical-stage biotechnology company developing treatments for rare muscle disorders. It had no approved products and generated no revenue. Its lead candidate, EDG-5506, is being developed for Duchenne and Becker muscular dystrophy (DMD and BMD); EDG-5440 and EDG-002 remained preclinical.
Key financial metrics
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $32.2 million | $15.0 million |
| General and administrative expense | $11.0 million | $2.2 million |
| Total operating expenses | $43.2 million | $17.2 million |
| Operating loss | $43.2 million | $17.2 million |
| Interest income | $0.4 million | $0.1 million |
| Net loss | $42.8 million | $17.1 million |
| Net loss per share, basic and diluted | $1.14 | $23.17 |
| Net cash used in operating activities | $33.5 million | $14.6 million |
- Liquidity: At December 31, 2021, cash and cash equivalents were $15.6 million and available-for-sale marketable securities were $265.2 million, totaling approximately $280.8 million. Management said existing resources were expected to fund its planned operations for at least 12 months.
- Debt and balance sheet: The company reported no debt outstanding. Total assets were $285.2 million, total liabilities $10.9 million, and accumulated deficit $77.0 million at year-end.
- Cash flows and financing: Investing activities used $242.2 million, largely reflecting purchases of marketable securities, rather than operating investment alone. Financing provided $186.4 million, primarily from the March 2021 IPO, which generated $186.1 million net proceeds.
- Margins: Not meaningful because the company had no revenue. No product-level profitability was reported.
- Other comprehensive loss: $0.5 million, reflecting unrealized losses on available-for-sale securities.
Material changes versus the prior year
- Net loss increased to $42.8 million from $17.1 million. R&D expense rose by $17.2 million, driven by EDG-5506 clinical development, discovery and preclinical work, and higher personnel costs.
- G&A expense increased by $8.8 million, reflecting public-company costs, higher headcount and stock compensation, directors’ and officers’ insurance, and professional fees.
- The IPO and conversion of all preferred stock substantially changed the capital structure. The reported per-share loss is not directly comparable year over year because weighted-average shares changed substantially following the IPO and conversion.
- Marketable securities increased following the IPO; year-end cash and cash equivalents declined as funds were invested in those securities.
Outlook, commentary and risks
- EDG-5506 development: The company planned an open-label, one-year BMD study and Phase 2 trials in BMD in the first half of 2022 and pediatric DMD in the second half of 2022. It also anticipated selecting an EDG-002 cardiac candidate in the second half of 2022. These are forward-looking plans, not guaranteed outcomes.
- Clinical evidence: The filing describes Phase 1 results in healthy volunteers and adults with BMD as generally well tolerated, with reductions in muscle-damage biomarkers. The BMD Phase 1b cohort was small (five treated participants and two placebo participants) and dosing lasted 14 days; biomarker changes do not establish clinical benefit or disease modification. The BMD topline results were announced in January 2022, after the reporting year.
- Funding: The company expects continued losses and significant R&D spending and states it will require substantial additional capital to complete development and commercialization. The stated 12-month runway depends on assumptions and is not assurance of future financing or approval.
- Execution and supply risks: The company relies on third parties for clinical trials and manufacturing. It reported no long-term supply arrangement or redundant manufacturer for EDG-5506, creating potential supply and trial-delay exposure.
- Other risks: Key uncertainties include clinical and regulatory failure, COVID-19-related enrollment or supply disruption, competition, intellectual-property challenges, limited rare-disease patient populations, and uncertain future coverage and reimbursement.
- Unusual and subsequent items: In January 2022, the company signed a new Boulder office and laboratory lease with an approximately $3.3 million total minimum payment commitment over an 84-month term. No material legal proceedings were reported. The independent auditor issued an unqualified opinion; management concluded disclosure controls were effective, while the filing did not include an auditor attestation on internal control over financial reporting.
Important facts for investors to verify
- Progress, enrollment, safety, and clinically meaningful outcomes—not only biomarker changes—in the planned BMD and DMD trials.
- Cash runway against actual operating burn, planned trial costs, and any subsequent financing; confirm the composition and liquidity of the marketable-securities portfolio.
- Whether the company establishes backup manufacturing capacity or longer-term supply arrangements for EDG-5506.
- Regulatory feedback on endpoints, trial design, and any accelerated-approval or breakthrough-therapy strategy; neither pathway is assured.
- Execution and costs of the new lease, along with the effects of stock-based compensation and potential share dilution.